Ledipasvir

Category: pharmacological

Pharmacological Mechanism

HCV NS5A inhibitor — disrupts NS5A protein function, blocking viral replication and assembly. Co-formulated with sofosbuvir as Harvoni for genotype 1/4/5/6 HCV — 12-week course with > 95% cure rate.

Half-Life (t½)

PO: 47h

Dosing Guidelines

• PO: Typical 90mg (Range: 90 - 90 mg)

Target Organ Systems

• immune-hematologic